
|Articles|January 16, 2015
- Vol 32 No 1
- Volume 32
- Issue 1
Talk Radio, 2 am
Author(s)Richard M. Berlin, MD
I’m driving home from the ER, not ready for sleep, eaten up by memories of my mistakes...
Advertisement
I’m driving home from the ER,
not ready for sleep, eaten up
by memories of my mistakes,
a man on the radio telling me
not to worry because I can learn
to control my mind. He says
thoughts are like puppies
we can paper-train and teach
to be obedient. He says
one day that puppy will calm down,
cuddle up, and lick my face.
But who is this guy kidding?
My mind isn’t a puppy tonight-
it’s a wild tiger,
and it’s ripping out my heart.
Articles in this issue
over 11 years ago
Does TMS Hold Promise for Generalized Anxiety Disorder?over 11 years ago
Managing Anxiety in the Medically Illalmost 12 years ago
Mental Health Benefits of Exercise in Childrenalmost 12 years ago
Gone Girl by Gillian Flynnalmost 12 years ago
How to Fix the Broken Mental Health System: Ten Crucial Changesalmost 12 years ago
Brain Stimulation With ECT: Neuroscience Insights From an Old Treatmentalmost 12 years ago
In With the Old, Out With the Newalmost 12 years ago
The Dynamics of Psychosis: Therapeutic Implicationsalmost 12 years ago
A Rational Suicide?Advertisement
Related to this article

Check out our pipeline updates from October!

Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.

HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.

Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.

A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.

National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.

GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
4
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
5

